Dual-drug nanocarriers for gout therapy: targeted co-delivery of anti-inflammatory and urate-lowering agents: a review
EXCLI Journal · 13.11.2025 · 24 · 1555-1593
DOI: 10.17179/excli2025-8871 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift EXCLI Journal, online erschienen am 13.11.2025. Verfasst von Nisha Rata Karusan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Faculty of Science, Universiti Malaya, 50603 Kuala Lumpur, Malaysia. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Gout, a prevalent form of inflammatory arthritis, arises from the deposition of monosodium urate crystals in joints due to chronic hyperuricemia. Current pharmacologic monotherapies such as xanthine oxidase inhibitors, uricosurics, NSAIDs, corticosteroids, and colchicine are often limited by inadequate dual-action efficacy, suboptimal bioavailability, and systemic side effects. Emerging nanocarrier-based drug delivery systems offer a promising alternative by improving pharmacokinetics and enhancing targeted delivery to inflamed tissues. While co-encapsulation of multiple therapeutics remains underexplored in gout, advances in related inflammatory diseases support its future application. This review explores the limitations of conventional gout therapies and highlights recent advancements in nanocarrier technologies, including liposomes, niosomes, and ethosomes, for delivering both anti-inflammatory and urate-lowering agents. Special attention is given to functionalization strategies that allow for site-specific delivery and sequential drug release, particularly in the acidic and oxidative microenvironments characteristic of acute gout flares. Co-delivery of agents such as allopurinol or febuxostat with NSAIDs or corticosteroids may reduce pill burden, improve therapeutic synergy, and enhance patient adherence. While clinical translation remains in early stages, the mechanistic rationale and encouraging preclinical outcomes of responsive, functionalized nanocarriers underscore their potential to advance precision medicine in gout management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemistry, Faculty of Science, Universiti Malaya, 50603 Kuala Lumpur, Malaysia.
- Centre for Fundamental and Frontier Sciences in Nanostructure Self-Assembly (FSSA), Department of Chemistry, Faculty of Science, Universiti Malaya, 50603 Kuala Lumpur, Malaysia.
- Universiti Malaya Community Engagement Centre (UMCares), Universiti Malaya, 50603 Kuala Lumpur, Malaysia.
- Undergraduate Medical Study Program, Faculty of Medicine and Health, Institut Teknologi Sepuluh Nopember, Surabaya, East Java 60111, Indonesia.
- Department of Oral Biology, Faculty of Dentistry, Universitas Airlangga, Surabaya, East Java 60132, Indonesia.
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Universiti Malaya, 50603 Kuala Lumpur, Malaysia.
Zitieren
APA
Karusan, N. R., Tajuddin, H. A., Mat Radi, N. A., Karimah, R., Soesilawati, P., Mahmood, S., & Ahmad, N. (2025). Dual-drug nanocarriers for gout therapy: targeted co-delivery of anti-inflammatory and urate-lowering agents: a review. EXCLI Journal, 24, 1555-1593. https://doi.org/10.17179/excli2025-8871
Vancouver
Karusan NR, Tajuddin HA, Mat Radi NA, Karimah R, Soesilawati P, Mahmood S, et al. Dual-drug nanocarriers for gout therapy: targeted co-delivery of anti-inflammatory and urate-lowering agents: a review. EXCLI Journal. 2025;24:1555-1593. doi:10.17179/excli2025-8871
BibTeX
@article{Karusan2025,
author = {Karusan, Nisha Rata and Tajuddin, Hairul Anuar and Mat Radi, Nor Azlin and Karimah, Rumman and Soesilawati, Pratiwi and Mahmood, Syed and Ahmad, Noraini},
title = {Dual-drug nanocarriers for gout therapy: targeted co-delivery of anti-inflammatory and urate-lowering agents: a review},
journal = {EXCLI Journal},
year = {2025},
volume = {24},
pages = {1555--1593},
doi = {10.17179/excli2025-8871}
}
EUVIMED